GLF
CRSP icon

Groupe la Francaise’s CRISPR Therapeutics CRSP Stock Holding History

Groupe la Francaise’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300
Closed -$20.5K – 538
2025
Q3 		$20.5K Buy
+300
New +$17.2K ﹤0.01% 524

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Groupe la Francaise's CRSP Position: Q4 2025 in Review

Groupe la Francaise sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 300 shares — an estimated $20.5K sold.

Groupe la Francaise first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $20.5K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Groupe la Francaise reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Groupe la Francaise sold 300 CRISPR Therapeutics shares in Q4 2025, an estimated $20.5K.
  • Groupe la Francaise first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
  • Groupe la Francaise's CRISPR Therapeutics position peaked at $20.5K in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.